Novocure Presents Phase 2 PANOVA Results at ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy may be Safe as First-Line Treatment and Improve Survival of Patients with Advanced Pancreatic Cancer
Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of gemcitabine-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will present data on Friday, Jan. 22, 2016, from its ongoing phase 2 PANOVA clinical trial at the American Society of Clinical Oncology 2016 …